The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine
The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine: An Open-label, Single-arm And Multi-center Study for 16 Weeks
Sponsor: Sumitomo Pharma (Suzhou) Co., Ltd.
Terminated
Company's business decision
Other terminated trials from Sumitomo Pharma (Suzhou) Co., Ltd.
More terminations from Sumitomo Pharma (Suzhou) Co., Ltd.
A PHASE4 clinical study on Schizophrenia, this trial is terminated or withdrawn. The trial is conducted by Sumitomo Pharma (Suzhou) Co., Ltd. and has accumulated 6 data snapshots since 2021. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
May 2024 — Jul 2024 [monthly]
Terminated PHASE4
Status: Active Not Recruiting → Terminated
-
May 2023 — May 2024 [monthly]
Active Not Recruiting PHASE4
Status: Not Yet Recruiting → Active Not Recruiting
-
Nov 2022 — May 2023 [monthly]
Not Yet Recruiting PHASE4
▶ Show 1 earlier version
-
Feb 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE4
First recorded
Dec 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sumitomo Pharma (Suzhou) Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .